|
|
 | | | |
- close
- close
- close
- close
Merck & Co |
Benzinga
7 hrs ago
Comment
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
provided an update on the clinical program for preladenant, Merck's
investigational adenosine A2[A ]receptor antagonist for the treatment of
Parkinson's disease (PD). An...
FiercePharma
May 23
Comment
Drugmakers forked over more than $1 billion to doctors last year, significantly more than reported in 2011. And that's only the amounts we know about. According to a new data analysis by PharmaShine, reported in the Financial Times, that figure...
Reuters
May 23
Comment
Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for...
Benzinga
May 23
Comment
Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today provided the following statement after the conclusion of the
Peripheral and Central Nervous System Drugs Advisory Committee meeting
of the U.S. Food...
FiercePharma
May 22
Comment
Generic competition, sales woes and R&D disappointments have put revenue on the decline and Merck in hot water, with the pharma giant earlier this month promising to buy back as much as $15 billion in shares. And yesterday, the company started in...
StreetInsider.com
May 21
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Stock+Buybacks/Merck+%28MRK%29+Enters+%245B+Accelerated+Buyback+w+Goldman/8359731.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
